Liquid biopsy enhances MRI studies of breast cancer patients
April 10, 2021 -- Adding liquid biopsy to magnetic resonance imaging (MRI) may improve the ability to gauge breast cancer treatment response, according to research presented April 10 at the American Association for Cancer Research annual meeting. Read More
Lucira Health assay spots 'double mutant' COVID-19 variant
April 9, 2021 -- Lucira Health said it can successfully identify the "double mutant" variant of COVID-19 with its Lucira molecular test kit. Read More
Hologic acquires Mobidiag for $795M
April 8, 2021 -- Hologic announced it has agreed to acquire Mobidiag, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation. Read More
Nucleix secures $55M in funding for lung cancer test
April 7, 2021 -- Liquid biopsy company Nucleix has secured $55 million to advance Lung EpiCheck, an early detection lung cancer test based on methylation technology. Read More
Mologic lands NIH funding for COVID-19 rapid antigen self-test
April 6, 2021 -- Mologic said that its COVID-19 rapid antigen self-test for home use has been awarded funding under the U.S. National Institutes of Health Rapid Acceleration of Diagnostics initiative. Read More
Delfi begins lung cancer study
April 1, 2021 -- Delfi Diagnostics announced the start of a national trial to evaluate its liquid biopsy test for early lung cancer detection. Read More
Thermo Fisher to launch new qPCR system
March 25, 2021 -- Thermo Fisher Scientific announced it has completed a U.S. Food and Drug Administration listing to launch its Applied Biosystems QuantStudio 5 Dx real-time polymerase chain reaction (qPCR) system. The new system simplifies molecular diagnostic workflows for infectious disease, oncology, and COVID-19 testing, according to the company. Read More
Numares seeks FDA nod for NMR platform
March 24, 2021 -- Numares has submitted a 501(k) application to the U.S. Food and Drug Administration (FDA) for its Axinon nuclear magnetic resonance (NMR) IVD platform for metabolomics-based and artificial intelligence-driven diagnostics. Read More
Lucence, Waseda University partner on liquid biopsy test
March 24, 2021 -- Lucence and Waseda University in Japan will develop a liquid biopsy laser-based imaging platform for early cancer detection. The technology captures thousands of high-resolution individual images of circulating tumor cells and clusters from a blood sample. Read More
FDA approves new uses for Natera's MRD test
March 24, 2021 -- The U.S. Food and Drug Administration (FDA) has granted two breakthrough device designations covering new intended uses for Natera's Signatera molecular residual disease (MRD) test. Read More